ICAM1 and neoplasm: It is composed of a rationally designed tumor‐targeting ICAM1 antibody‐drug conjugate (ADC) with an optimized chemical linker and cytotoxic payload, complemented by a magnetic resonance imaging (MRI)‐based molecular imaging approach to noninvasively evaluate the efficiency of ICAM1‐targeting immunotherapy.